Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaChris H. Polman, Jerry S. Wolinsky, Stephen C. Reingold et al.|Annals of Neurology|2011Cited by 9.8k
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosisXavier Montalbán, Frauke Zipp, Ralf Gold et al.|Multiple Sclerosis Journal|2018Cited by 706
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trialRalf Gold, Gilmore O’Neill, Gavin Giovannoni et al.|The Lancet|2013Cited by 287
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trialGıancarlo Comı, Jeffrey A. Cohen, Ludwig Kappos et al.|The Lancet Neurology|2019Cited by 286
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trialJeffrey A. Cohen, Ludwig Kappos, Gıancarlo Comı et al.|The Lancet Neurology|2019Cited by 279